~~<i id='267024914D'><strike id='267024914D'><tt id='267024914D'><pre id='267024914D'></pre></tt></strike></i>~~

Home» leisure time» leisure time

leisure time

author：focus 2025-09-30 03:12:21 Page View：38335

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Why scientists need input from humanists on sensitive research
Next article： Medicare details structure of new drug price negotiation program

focus

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

WuXi out of biotech trade group, U.S. and China relations to blame

AdobeWASHINGTON—TheBiotechnologyInnovationOrganization,anindustrytradegroup,iscuttingtieswithChinese

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

AdobeAcadiaPharmaceuticalssaidMondaythatitsapprovedmedicinecalledNuplazidfailedtoimprovethesocialand